RemedyOne, Author at RemedyOne

Breathing Easier: The Quest for Cost-Effective Asthma Care

Treating Mild to Moderate Asthma in Adolescence and Adults The objectives for treating moderate, persistent asthma in adolescents and adults are to reduce symptoms, avert flare-ups, and restore normal lung function, to enhance the quality of life. For first-time patients, the initial therapy is tailored based on the severity of their condition. National guidelines suggest […]

Breathing Easier: The Quest for Cost-Effective Asthma Care Read More »

Multiple Sclerosis: Evolving Approaches to Treatment

Uncategorized / RemedyOne

Regarded as the leading progressive neurological disease affecting young adults, multiple sclerosis (MS) often strikes during life’s pivotal moments—when individuals are embarking on careers or starting families. The global prevalence of MS is rising, particularly affecting women. In the US alone, over a million people grapple with its often-debilitating effects. Alongside the physical and emotional

Multiple Sclerosis: Evolving Approaches to Treatment Read More »

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars

Clinical Insights, News / RemedyOne

Uncover what could happen with Humira and the biosimilar market in 2023 While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and knock Humira

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars Read More »

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News

Clinical Insights, News / RemedyOne

A Fox News article recently quoted RemedyOne EVP of clinical services Rob Louie on xylazine, a potent veterinary drug that has seen a recent uptick in illicit human use. Rob helped add context to an alert from the U.S. Drug Enforcement Administration on xylazine. Below is the complete interview, which Rob prepared for in collaboration

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News Read More »

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars

Clinical Insights, Formulary Management / RemedyOne

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »

Unpacking the Biosimilar Buzz

Clinical Insights, Formulary Management / RemedyOne

As industry experts, it’s the number one topic we’re being asked to comment on. While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and

Unpacking the Biosimilar Buzz Read More »

Six Months After Authorization, What Do We Know About Paxlovid?

Clinical Insights, Formulary Management / RemedyOne

See this article by RemedyOne EVP of clinical services Robert Louie as it originally appeared in Pharmaphorum. It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with

Six Months After Authorization, What Do We Know About Paxlovid? Read More »

How the Pharmaceutical Industry Can Turn the Tide on Mental Health

News / RemedyOne

May is Mental Health Awareness Month. RemedyOne president Ralph Pisano wrote this article for Fierce Healthcare about how the pharmaceutical industry can do more to address the mental health crisis. The stigma of mental health disorders is slowly disappearing, and that’s a very good thing. You see evidence of this everywhere: on TV and social

How the Pharmaceutical Industry Can Turn the Tide on Mental Health Read More »

Three Pharmacy Trends That Will Define 2022

Rebate Management / RemedyOne

See article as it originally appeared in MedCity News. The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year as well. Here are three key themes that will define the year ahead. Biosimilar interchangeability In 2021 the FDA approved the

Three Pharmacy Trends That Will Define 2022 Read More »

2022 Q1 RemedyOne Quarterly Pipeline Report

Clinical Insights / RemedyOne

Download our 2022 Q1 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest

2022 Q1 RemedyOne Quarterly Pipeline Report Read More »